Contact
Please use this form to send email to PR contact of this press release:
Celldex Therapeutics Initiates Phase 1 Study of New Bispecific Product Candidate CDX-527 in Solid Tumors
TO:
Please use this form to send email to PR contact of this press release:
Celldex Therapeutics Initiates Phase 1 Study of New Bispecific Product Candidate CDX-527 in Solid Tumors
TO: